Persistent anaemia symptoms Reported by the women · women with postpartum iron deficiency anaemia
It is very uncertain whether intravenous iron with oral iron changes persistent anaemia symptoms ‐ 1 week Visual Analogue Scale ≥ 7 compared with oral iron (Comparison 6) (very low certainty).
3 findings from 1 review
RR 1.75 [0.56, 5.46]
1 study · 72 participants
Very low
RR 0.6 [0.15, 2.33]
1 study · 72 participants
Very low
RR 3 [0.33, 27.5]
1 study · 72 participants
Very low
Infections ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anaphylaxis or evidence of hypersensitivity Clinical assessment · women with postpartum iron deficiency anaemia
1 finding from 1 review
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid probably leads to higher ulcer healing compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid probably leads to higher complete relief of rest pain compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in ulcer healing compared with placebo (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in complete relief of rest pain compared with placebo (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Incidence of acute bilirubin encephalopathy · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review